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Summary Mechanisms of anthracycline resistance have been investigated in a B16 murine melanoma cell
subline selected by continuous in vitro exposure to increasing concentrations of doxorubicin (DX). Altered
drug pharmacokinetics were observed in resistant B16 cells as compared to the sensitive counterpart. In fact,
cellular DX uptake - as determined by a fluorescence method - was lower in resistant than in sensitive cells.
Furthermore, drug efflux rate was shown to be higher in resistant than in sensitive cells; treatment of cells
with the metabolic inhibitor sodium azide decreased drug efflux rate in resistant but not in sensitive cells,
suggesting the presence of an energy-dependent drug extrusion mechanism in the resistant B16 cells. However,
since drug-induced cell killing did not correlate with cellular DX contents in sensitive and resistant cells, drug
resistance of B16 subline could not be completely explained by the observed differences in drug
pharmacokinetics. Since drug-induced DNA breaks have been related to drug cytotoxicity, DNA cleavage was
also measured by alkaline elution methods. The number of DNA breaks produced by DX was decreased in
resistant cells as compared to sensitive cells at the same cellular drug accumulation. The results are consistent
with the view that anthracycline resistance may be multifactorial and probably arises following multiple
biochemical changes.
Doxorubicin (DX) is one of the most active chemothera-
peutic agents for the treatment of human cancer (Davis &
Davis, 1979). However, tumour cells often develop resistance
to antitumour drugs, even in patients who were initially
responsive, and this may lead to therapeutic failure (Kaye &
Merry, 1985). Many leukaemia and solid tumour cell lines
have been selected for resistance to anthracyclines, in order
to study the mechanisms of cellular drug resistance. These
experimental models are often resistant not only to the
selecting drug but also to other unrelated compounds: this
phenomenon is known as multi-drug resistance (MDR)
(Wilkoff & Dulmadge, 1978; Chitnis et al., 1982). Altered
drug permeability of the plasma membrane of resistant cells
has been generally implied as the mechanism underlying
MDR (Inaba et al., 1979; Bates et al., 1985; Siegfried et al.,
1985) and MDR is associated with the overproduction of
high molecular weight membrane glycoproteins following
gene amplification (Van der Blieck et al., 1986; Riordan et
al., 1985; Slovak et al., 1986). However, multiple biochemical
modifications may be responsible for MDR, as reduced
drug-induced DNA cleavage was observed in resistant cells
(Capranico et al., 1986; Glisson et al., 1986), and over-
production of a 20Kd cytosolic protein was reported in
MDR cells selected with vincristine (Meyers et al., 1985).
A cell line of murine melanoma B16 was previously
selected by continuous in vitro exposure to increasing DX
concentrations. As previously described (Supino et al., 1986,
Formelli et al., 1986a), this cell subline was 200 times more
resistant to DX than the parental cell line, (ID50 2,000-2,200
versus 10-15ngml-1) and it showed biological and
biochemical properties different from those of the parental
sensitive cell line both in vitro and in vivo. The aim of the
present work was to investigate whether acquired resistance
of B16 cells to DX could be associated with altered
membrane transport and with differences in drug induced
DNA breakage.
Materials and methods
Drugs and chemicals
Doxorubicin (DX) was a gift of Farmitalia-Carlo Erba
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(Milan, Italy). Sodium azide (NaN3) was purchased from
Merck (Darmstadt, Germany). Immediately before use,
drugs were dissolved in distilled water and diluted in 0.9%
NaCl.
Cell lines and drug sensitivity assay
The B16 melanoma cell line (B16V) and the resistant variant
subline (B16VDXR) were cultured in RPMI 1640 medium
(Flow Laboratories, Irvine, Ayrshire, U.K.) supplemented
with 10% foetal calf serum (FCS) (Flow Laboratories),
0.03 mm Fe(CN)6K3 and antibiotics and maintained as
already described (Supino et al., 1986).
Drug activity was determined by the growth inhibition
test. Exponentially growing cells were treated with DX for
1 h at 37°C. After drug treatment, cells were washed with
saline solution, cultured in drug-free medium for 72h and
counted. Cell viability at the cell seeding and at the end of
the experiment was determined by trypan blue exclusion test.
Cell volume and DNA content
Cell diameters were measured immediately after detachment
by means of a microscope with calibrated eyepiece
micrometer and the cell volume was evaluated assuming the
cells to be spherical.
DNA content in cell cultures was measured according to
the method of Burton (1956).
Drug uptake and efflux
In order to measure cellular drug accumulation, expon-
entially growing cells were exposed to different DX
concentrations in complete RPMI 1640 medium at 37°C for
various periods of time. Cells were then washed with ice-cold
saline solution, detached and harvested in distilled water.
Drug was extracted in normal butyl alcohol and the
fluorescence intensity of organic phase was determined by a
fluorescence spectrophotometer (Perkin-Elmer MPF-44A) at
500 and 589 nm of excitation and emission wavelengths,
respectively. DX concentration was determined from a
calibration curve.
Experiments to evaluate the mechanisms of drug transport
were carried out in Hank's Balanced Salt Solution (HBSS).
NaN3 (10mM) was added 10min before DX and not
removed during drug treatment.
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Efflux was evaluated after 1 h drug treatment. At this time
DX was removed, cells washed with ice-cold saline solution
and replaced in drug-free HBSS. At different times cells were
detached and processed as above. The activity of glucose and
NaN3 on DX efflux was evaluated by adding these
compounds during drug uptake and/or efflux.
Alkaline elution assay
DNA single-strand breaks (SSB) were determined by alkaline
elution methods as essentially described by Kohn et al.
(1981) and reported elsewhere (Capranico et al., 1986).
Briefly, cell DNA was labelled with 0.05 puCi ml-1
[2-14C]thymidine (Amersham International, Amersham, U.K.)
for 30h. Cells were irradiated on ice with a '37Cs source
at 10.2Gymin-1. In the filter elution experiments, after
drug treatment or y-ray irradiation, cells were detached
mechanically, layered on polycarbonate membrane filters
(2.0pm pore-size, 25 mm diameter; Nucleopore Corp.,
Pleasanton, CA, U.S.A.) and washed with ice-cold saline
solution. Cells were then lysed with 0.5mgml-1 proteinase
K (Merck, Darmstadt, Germany) in the lysing solution
containing 2% SDS, 0.1 M glycine and 25mm EDTA, pH 10.
The DNAs on the filters were eluted with 0.1% SDS, 20mM
EDTA (acid form) and tetrapropylammonium hydroxide
(Eastman Kodak, Rochester, NY, U.S.A.) at pH 12.15.
DNA-SSB were calculated as previously reported
(Capranico et al., 1986) and expressed as rad-equivalents.
Results
Drug uptake
DX contents as a function of time in B16V and B16VDXR
cells at different drug concentrations are shown in Figures
1a, b. After 1 h treatment with the same amount of DX
(0.002-0.02mM), cellular drug content was 3-fold higher in
sensitive cells than in resistant cells. Nevertheless, after
longer periods of treatment (e.g. 4h) the difference increased
up to 5- or 10-fold. In fact, DX uptake in B16V cells
increased rapidly in the first hour and then at a slower rate,
doubling the drug content after 4h treatment. On the
contrary, no further increase in the drug content was
observed in B16VDXR cells after 1 h exposure. Furthermore,
a dependence upon extracellular drug concentration was
observed in both cell lines, with no saturation at 0.02mm in
B16V cells and 0.08mM in B16VDXR cells.
Thin layer chromatography analyses of cellular drug
extracts detected no metabolites under our experimental
conditions (data not shown).
Drug efflux
DX efflux of both B16V and B16VDXR cells was evaluated
after 1 h exposure to different drug concentrations. Table I
shows that the maximum efflux was reached after 2h in both
cell lines and only a further slight reduction in the cellular
drug content could be observed after 24h. However, the rate
of drug efflux was different being 20% and 50-60% after
45min and 40-50% and 70% after 120min in B16V and
B16VDXR cells respectively. Therefore, drug efflux was
faster and higher in resistant cells than in sensitive cells.
Table I also shows a dependence of the extent of the efflux
on the extracellular drug concentration. In fact, the
percentage of drug efflux after 24h is higher at higher doses
of DX than at lower doses either in sensitive or in resistant
cells. These data suggest that a higher fraction of drug was
bound to cell structures at low rather than at high
concentrations.
The difference in cellular drug content is even more
relevant if we consider that the cell volume of B16V cells is
smaller than that of B16VDXR cells (Table II). In fact, cell
diameter was 19.8+1.87,um in B16V and 25.8+ 1.32 pm in
B16VDXR cells. Therefore, cell volume was 4,055pIm3 in
sensitive cells and 8,973pm3 in resistant ones. The
corresponding DNA content was 14.4pg 10-6 cells and
23.4pg 10-6 cells respectively.
When extracellular and intracellular DX concentrations
were compared for the two cell lines (Table II) we observed
that while in sensitive cells the ratio of intracellular/
extracellular drug concentration after 1 h of uptake was
63-84, in the resistant ones this ratio was - 10. This value
decreased to 27-50 and 1.25-3 respectively after 24h of
efflux. These data point out that with the same DX concen-
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Figure 1 Uptake of DX in (a) B16V and (b) B16VDXR cells.
Drug uptake was evaluated at different periods of time and doses
as described in Materials and methods. Standard error of each
point was <10% of mean value; each point is the mean of 2
determinations obtained from 2 independent experiments.
* 0.0004mM; O 0.002mM; A 0.006mM; O O.OllmM;
O 0.02mM -in B16V cells. * 0.002mM; A 0.006mM; * 0.011 mM;
* 0.02mM; 0 0.08mM - in B16VDXR cells.
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Table I Cellular DX content evaluated at different doses and after different times ofefflux
Cellular DX content (mg 10-6 cells)a
DX concentration in the culture medium (mM)
Efflux
time 0.08 0.02 0.002 0.0004
B16V Zero 2,700+ 40 370+52 76+1.1
45min ND 2,240+ 17 (83%)b 290+ 1.0 (81%) 58+1.1 (83%)
120min 1,320+ 46 (49%) 210+ 0.5 (57%) 60+1.1 (66%)
24h 1,210+ 28 (45%) 200+ 0.5 (55%) 46+1.7 (62%)
B16VDXR
Zero 3,200+690 920+ 170 102+ 10.0
45min 600+ 86 (19%) 330+ 17 (36%) 48+ 1.1 (47%) ND
120min 440+ 98 (14%) 270+ 28 (30%) 34+ 2.8 (34%)
24h ND 240+ 17 (27%) 30+ 2.3 (30%)
aData, expressed as mg 10-6 cells, are the mean of 2 replicates in 3 experiments+s.e.; b% indicates
the efflux compared to time zero.; ND=not done.
Table II Relationship between extracellular and intracellular DX concentrationa
Intracelluar DX
Extracellular Intracellular DX concentration after
Cell DX concentration after 1 h ofuptake and
line concentration Ih ofuptake+s.e. 24h ofefflux±s.e.
(int/ext) (int/ext)
mM mM ratiob mM ratio
B16V 0.02 1.220+0.109 61 0.540+0.098 27
0.011 0.720+0.046 65 ND
0.006 0.380+0.034 63 ND
0.002 0.160+0.040 80 0.092+0.011 46
0.0004 0.031 +0.005 78 0.020+0.014 50
B16VDXR
0.08 0.680+0.103 8.5 0.100+0.008 1.25
0.02 0.190+0.017 8.5 0.049+0.007 2.45
0.011 0.100+0.011 9.1 ND
0.006 0.073+0.011 12.2 ND
0.002 0.021 +0.009 10.5 0.006+0.003 3.00
aIntracellular DX concentration is the ratio between the intracellular DX content evaluated in
3 independent experiments and the cell volume; bRatio between intracellular DX concentration
and extracellular DX concentration in the culture medium; ND=not done.
tration in the culture medium, the intracellular concentration
of the drug in B16V cells is much higher than in B16VDXR
cells either after short or long time of efflux.
Cellular drug concentration and cytotoxicity
In order to compare cellular drug content and DX activity in
B16V and B16VDXR lines, the cell toxicity was reported as
a function of the cellular drug concentration immediately
after DX exposure (Figure 2a) or after 24h (Figure 2b) from
the end of exposure. Increasing cellular drug content caused
an increased cytotoxicity, although a lack of correlation
between the two parameters was evident in both cell lines.
Indeed, the cellular concentration that induced 50% of cell
death was 4-10 fold higher in resistant than in sensitive cells.
Drug transport and cellular metabolism
In order to study the mechanism of drug transport in our
melanoma cells, we evaluated the effect of the treatment with
sodium azide (NaN3) and/or with glucose on drug uptake
and efflux. Since no differences were found in pharmaco-
kinetics experiments performed in complete culture medium
or in HBSS (data not shown), the studies on the mechanisms
of drug transport were performed in HBSS, as under these
conditions it is possible to evaluate the activity of NaN3, an
inhibitor of oxidative phosphorylation. Glucose was used as
an energy source thus having an antagonistic effect on
NaN3.
Figure 3a shows that both NaN3 (10mM) and glucose
(5.5mM) do not affect either the uptake or the efflux of DX
in B16V cells. On the contrary, an increase of - 20% in the
DX uptake was observed in B16VDXR cells in the presence
of NaN3 (Figure 3b). This increased uptake seems to be due
to the observed decrease of efflux from 74 to 50%. In fact,
this value of efflux was restored by the addition of glucose
to the culture medium.
These data suggest different mechanisms of efflux in our
two cell lines. Drug extrusion seems to be mainly due to a
passive transport in sensitive cells, whereas in resistant cells
the efflux is regulated by an active transport. However, an
alternative explanation would be an energy-dependent release
of drug from intracellular binding sites.
Formation ofDNA breaks
Since DX resistance could not be completely explained by
differences of drug pharmacokinetics between the two cell
lines, we examined the formation of DNA-SSB subsequent
to drug treatment, since it was shown that reduced DNA
cleavage by anthracyclines is associated with acquired drug
resistance of P388 leukaemia cells (Capranico et al.,
1986; 1987).DOXORUBICIN EFFECTS IN RESISTANT CELLS 145
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again a different efflux probably due to free-drug not linked
to cellular structures. The intracellular concentrations of DX
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Figure 2 Relationship between cellular DX concentration and
cell survival. (a) Cellular DX concentration evaluated after 1 h of
uptake; (b) Cellular DX concentration evaluated after 1 h of
uptake and 24h ofefflux.
For the evaluation of cell survival, cells were treated for 1 h
and counted 72h later as reported in Materials and methods.
0 B16V; * B16VDXR.
DNA-SSB induced by 1 h treatment with DX in sensi-
tive and resistant B16 cells were reported in Figure 4 as a
function of cellular drug accumulation. In the range of drug
concentrations used, DNA-SSB frequency seemed to be
lower in resistant than in sensitive cells at the same cellular
drug uptake. On the contrary, y-rays induced the same
effects on DNA in the two melanoma cell lines (not shown).
Relatively linear alkaline elution curves were expected in
these experiments if drug treatment produced predominantly
random DNA breakage. On the contrary, in sensitive B16
cells the highest concentration of drug yielded curvilinear
elution profiles (not shown). Thus, in this case DNA breaks
were probably underestimated, as a significant fraction of
cells can be in a non-proliferating state. These results suggest
that intracellular drug interactions may also be modified in
B16VDXR cells.
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Figure 3 Uptake and efflux of DX in the presence or absence of
10mM NaN3 or 5.5mM glucose. The arrow indicates the time
when the efflux was started, i.e. after 1 h of incubation in the
presence of DX, as described in Materials and methods. Each
point is the mean of 2 determinations obtained from 3
independent experiments +s.e.
(a) B16V cells treated with 0.0004mM DX; (b) B16VDXR cells
treated with 0.02mm DX. O O uptake and efflux without
NaN3; A\ A uptake and efflux with NaN3; A /A
and A------A uptake with NaN3 and efflux with glucose. Open
symbols: B16V; closed symbols: B16VDXR.
Discussion
In the present study we show that DX resistance of
B16VDXR cells is associated with lower drug uptake and
retention as compared to B16V cells. Furthermore,
biochemical modifications of drug action at intracellular
level are likely to be present in resistant cells. At the same
extracellular drug concentration the efflux was lower in B16
sensitive cells causing an intracellular drug concentration 7-
10 fold higher than in resistant ones. Moreover, the slope of
the efflux was faster in resistant than in sensitive cells. Thus,
besides a different ratio between the amount of DNA (that is
1 1.6 times higher in resistant than in sensitive cells) and
the different drug concentration, a different time of exposure
of DNA to DX may be a factor for resistance in these cells.
The results reported in Table I showing a higher and
faster drug efflux at high concentrations on both lines
indicate that an intracellular binding saturation seems to be
reached both in B16V and B16VDXR cells. Moreover, the
increase of the intracellular/extracellular ratio of drug
concentration at low extracellular drug amounts points out
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Figure 4 Relationship between DNA-SSB and cellular drug
content in B16V (0) and B16VDXR (0) cells. Cells were
exposed to DX for 1 h at 37°C and processed as described in
Materials and methods. Each point is the mean of 3 independent
determinations +s.e.
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not only during the uptake but also after 2 and 24h of
efflux, thus indicating a drug sequestration in cellular
structures.
Our findings on drug uptake agree with those reported on
P388 (Inaba et al., 1979) and Ehrlich ascites tumours
(Skovsgaard, 1977). In fact, drug influx in sensitive and
resistant cells is independent of energetic metabolism, while
drug efflux - at least in resistant cells - is reduced by NaN3,
an inhibitor of oxidative phosphorylation. Since the resistant
subline has probably arisen by selection of a low percentage
of cells already present in the parental sensitive population
(Supino et al., 1986), it is possible that the selection was
caused by an enhanced active mechanism of DX extrusion.
The DX concentrations used in these in vitro experiments are
those achievable in the plasma of mice treated with the drug
(Formelli et al., 1986b). These in vitro studies are of
considerable help to investigate the cell drug pharmaco-
kinetic properties, although it is known that other factors
like drug metabolism, tumour vascularization, tumour
burden, schedule and route of administration may affect the
in vivo activity of DX.
The present data also show a lack of correlation between
cytotoxicity and intracellular drug concentration in the two
cell lines. To obtain a 50% of cell survival in resistant cells,
it was necessary a total intracellular drug concentration 4-10
fold higher than in sensitive cells. This difference can be
partially explained by the previously reported observation
(Supino et al., 1986) that after a short treatment the
intracellular distribution of DX is different, being the
nucleus/cytoplasm ratio double in sensitive as compared to
resistant cells.
However, since protein-associated DNA breaks induced by
intercalating drugs have been related to drug cytotoxicity
(Pommier et al., 1985; 1986) and a decreased effect on DNA
has been described in P388 cells resistant to DX as compared
to sensitive cells (Capranico et al., 1986; 1987), we also
measured DX-induced DNA-SSB in sensitive and resistant
melanoma cells. Though DX-induced DNA-SSB levels are
higher in sensitive leukaemia cells than in sensitive B16
melanoma cells, our results show that DNA fragmentation
produced by DX is reduced in resistant B16 cell line as
compared to sensitive counterpart at the same cellular drug
content. This reduction was less marked than that observed
in P388 cell system (Capranico et al., 1986; 1987). It was
even less if we consider that the cell volume of B16VDXR
cells is 2-fold higher than that of B16V cells. Therefore, in
this cell model the reduction of DX-induced cytotoxicity and
DNA breaks is probably due to impaired drug uptake.
However, it is still possible that a change of drug-DNA
interaction may be present in B16VDXR cells. Further
studies will better elucidate this point. In conclusion, these
results are consistent with the hypothesis that MDR may be
multifactorial (Capranico et al., 1987) and probably arises
following multiple changes such as altered drug membrane
transport, intracellular drug distribution and drug-induced
effects on DNA.
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